Global Neuropathic Pain – Epidemiology Insights and Forecast Report (Top 32 Markets) – 2020 To 2040

Global Neuropathic Pain Epidemiology Insights

Thelansis’s “Global Neuropathic Pain Epidemiology Insights and Forecast Report (Top 32 Markets) – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, kidney biopsy cases, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Neuropathic Pain Overview

Neuropathic pain is a chronic condition caused by injury or dysfunction of the nervous system, leading to abnormal pain signaling. Unlike nociceptive pain from tissue damage, it produces burning, shooting, or electric‑like sensations, often accompanied by allodynia (pain from non‑painful stimuli) and hyperalgesia (exaggerated pain response). Common causes include diabetes, shingles, chemotherapy, spinal cord injury, and multiple sclerosis. Diagnosis is clinical, supported by neurological examination, and treatment typically involves medications such as gabapentin, pregabalin, duloxetine, or amitriptyline, with topical agents like lidocaine or capsaicin for localized pain. In resistant cases, interventional approaches such as nerve blocks or spinal cord stimulation may be considered.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Deliverables format and updates*:

• Access to an interactive epidemiology platform with downloadable Excel and PPT files.
• Global findings
• G8 findings
• Regional findings
• Country-specific findings
• Others*: regular updates, customizations, epidemiologist support
• *As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.

Key business questions answered:

• 20-year historical and forecast data (2020–2040)
• Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
• Granular patient population coverage by year and geography
• Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
• Patient funnels
• Country comparisons
• Relevant clinical variables (e.g., staging/classification/severity)
• Insights driven by robust research and estimates:
• Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
• Primary market research with KOLs
• RWD analysis using claims and EHR datasets
• Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)

Read more: Global Neuropathic Pain – Epidemiology Insights and Forecast Report (Top 32 Markets) – 2020 To 2040